- Biocept (NASDAQ:BIOC +3.4%) announces a collaboration with Catalyst Pharmaceuticals (CPRX +3.1%) under which it will provide its Target Selector platform to screen participants in a Phase 3 study assessing Firdapse (amifampridine phosphate) in patients with Eaton Myasthenic Syndrome (LEMS).
- Specifically, Catalyst will offer the test at no charge to patients to monitor the early onset or recurrence of small cell lung cancer (SCLC) during the long-term extension phase of the trial. Subjects will have access to the liquid biopsy test every six months for up to two years.
- About half of LEMS patients have a form of the disease that is associated with an increased risk of developing SCLC. Approximately 90% of these patients develop tumors within two years of the LEMS diagnosis.
- Terms of the agreement are not disclosed.
- Previously: Enrollment underway in Catalyst Pharma's second late-stage study of Firdapse in LEMS (Dec. 15, 2016)